Medtronic’s turnaround is getting harder to ignore.

$MDT Q4 FY2026: Revenue: $9.81B vs. $9.66B expected Non-GAAP EPS: $1.55 vs. $1.54 expected Revenue growth: +9.9% Organic growth: +6.6% Free cash flow: $5.4B Cash + investments: $9.2B The standout number: Cardiac Ablation Solutions revenue jumped 78% globally, including 124% growth in the U.S. That helped drive 10.1% organic growth in Cardiovascular, Medtronic’s largest segment. Diabetes also grew 15% as reported, while Medical Surgical and Neuroscience both posted organic growth. For the full ye